Delafloxacin
From Self-sufficiency
| File:Delafloxacin.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
1-(6-amino-3,5-difluoro-2-pyridyl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-quinoline-3-carboxylic acid | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 189279-58-1 |
| ATC code | none |
| PubChem | CID 487101 |
| ChemSpider | 427049 |
| Chemical data | |
| Formula | C18H12ClF3N4O4 |
| Molar mass | 440.76 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Delafloxacin (originally RX-3341) is a fluoroquinolone antibiotic being developed by Rib-X Pharmaceuticals, Inc.
It is more active (lower MIC90) than other quinolones against Gram-positive bacteria such as MRSA.
Phase II clinical trials have reported good results.[1][2][3] for example compared with tigecycline[4]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />| 50px | This systemic antibacterial-related article is a stub. You can help ssf by expanding it. |
- ↑ http://www.bio-medicine.org/biology-technology-1/Rib-X-Pharmaceuticals-Announces-Positive-Phase-2-Study-Results-for-Delafloxacin-and-a--2425-Million-Financing-10093-1/
- ↑ http://clinicaltrials.gov/ct2/show/NCT00719810
- ↑ http://www.medicalnewstoday.com/articles/132200.php "Rib-X Pharmaceuticals Reports Positive Top-Line Results From Phase 2 Study Of Delafloxacin" 9 Dec 2008
- ↑ http://www.citybizlist.com/lstg/lstgDetail.aspx?id=45749 "ABS Ventures Joins $25M Series D Rib-X Pharmaceuticals Inc." 5 Feb 2009
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Antibiotic stubs
- Fluoroquinolone antibiotics
- 2Fix
